Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:OVID

Ovid Therapeutics Q3 2026 Earnings Date & Estimates

Ovid Therapeutics logo
$2.37 -0.10 (-4.05%)
Closing price 10/22/2026 04:00 PM Eastern
Extended Trading
$2.35 -0.02 (-0.84%)
As of 05:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ovid Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ovid Therapeutics in Q3 2026

Ovid Therapeutics is expected to post earnings of -$0.08 per share on revenue of $0.03 million. In the same quarter a year earlier Ovid Therapeutics reported -$0.17 per share on revenue of $0.13 million. Ovid Therapeutics last reported on August 13, 2026, posting -$0.08 per share and beating the -$0.1150 consensus estimate. Ovid Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.08
Expected Revenue
$0.03 million
Prior-Year EPS
-$0.17
Prior-Year Revenue
$0.13 million
Expected Revenue Growth
-76.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.08 (Beat by +$0.0350)
Last Quarter Revenue
$0.73 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Ovid Therapeutics Q3 2026 Earnings FAQ

Ovid Therapeutics (NASDAQ:OVID) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Ovid Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Ovid Therapeutics to post earnings of -$0.08 per share for Q3 2026.

The consensus revenue estimate for Ovid Therapeutics is $0.03 million for Q3 2026.

Ovid Therapeutics Earnings Headlines

Head to Head Comparison: Lyra Therapeutics (OTCMKTS:LYRA) & Ovid Therapeutics (NASDAQ:OVID)
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148299
Ovid Therapeutics (NASDAQ:OVID) Stock Rated "Outperform" in New Coverage at Wolfe Research
October 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31129771
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
October 23 at 1:00 AM  |  InvestorPlace (Ad)
Ovid Therapeutics (NASDAQ:OVID) Stock Rated "Moderate Buy" by Wall Street Analysts
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109305
Cantor Fitzgerald initiates coverage of Ovid Therapeutics with overweight rating
October 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/cantor-fitzgerald-initiates-coverage-of-ovid-therapeutics-with-overweight-rating/ar-AA2dTLLN
Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ovid-therapeutics-ovid-stock-gets-091347114.html
See More Ovid Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ovid Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ovid Therapeutics and other key companies, straight to your email.

About Ovid Therapeutics

Ovid Therapeutics (NASDAQ:OVID) Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for epilepsies and other disorders of the central nervous system. The company’s research has concentrated on conditions with significant unmet medical needs, including rare epileptic and neurodevelopmental disorders.

Ovid’s pipeline has included soticlestat, an investigational therapy developed in collaboration with Takeda Pharmaceutical Company for developmental and epileptic encephalopathies such as Dravet syndrome and Lennox-Gastaut syndrome. The company has also investigated therapies targeting other neurological conditions, including the former program gaboxadol, which was evaluated for Angelman syndrome and other disorders.

Founded in 2014 and headquartered in New York, Ovid has advanced its programs through collaborations with larger pharmaceutical companies and clinical research networks serving patients internationally. Its development strategy has emphasized partnerships intended to support clinical testing, regulatory review and potential commercialization across global markets.

View Ovid Therapeutics Profile
Earnings Tools